NEJM and others summarize evidence that GLP-1 receptor agonists for type 2 diabetes and obesity reduce cardiovascular risk and slow kidney failure, with adverse events mainly gastrointestinal; Eric Topol notes inflammation is barely discussed in the review.
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure.
Adverse events are mostly gastrointestinal.
surprisingly, the word inflammation only appears once, in this diagram
GLP1 agonists - April 2026 NEJM review
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare